MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models

Activation of the mitogen-activated protein kinase (MAPK) pathway is frequent in cancer. Drug development efforts have been focused on kinases in this pathway, most notably on RAF and MEK. We show here that MEK inhibition activates JNK-JUN signaling through suppression of DUSP4, leading to activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Zheng, Vis, Daniel J., Bruna, Alejandra, Sustic, Tonci, van Wageningen, Sake, Batra, Ankita Sati, Rueda, Oscar M., Bosdriesz, Evert, Caldas, Carlos, Wessels, Lodewyk F. A., Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028652/
https://www.ncbi.nlm.nih.gov/pubmed/29795445
http://dx.doi.org/10.1038/s41422-018-0044-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028652/
https://www.ncbi.nlm.nih.gov/pubmed/29795445
http://dx.doi.org/10.1038/s41422-018-0044-4

Ejemplares similares